Age-Based Outcomes in Patients With mRCC Treated With First-Line Targeted Therapy or Checkpoint Immunotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Outcomes Based on Age in Patients With Metastatic Renal Cell Carcinoma Treated With First Line Targeted Therapy or Checkpoint Immunotherapy: Older Patients More Prone to Toxicity
J Geriatr Oncol 2020 Dec 31;[EPub Ahead of Print], CK Hermansen, F DonskovRenal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.